Use of ANAR for the therapy of opium withdrawal syndrome.
We studied the efficiency of ANAR containing antibodies to morphine (dilutions C300 and C200) in the therapy of patients with the opium withdrawal syndrome. In patients with moderate to severe forms of the opium withdrawal syndrome therapeutic activity of ANAR was comparable to that of standard symptomatic drugs. ANAR possessed vegetostabilizing, sedative, and analgetic properties. Treatment with ANAR allowed us to reduce doses of psychotropic and analgetic preparations and delay the development of withdrawal symptoms by 18-24 h.
Gofman
A G
AG
Moscow Institute of Psychiatry, Russian Ministry of Health.
Krylov
E N
EN
Kozhinova
T A
TA
Nizhnichenko
T I
TI
Khanykov
V V
VV
Sheveleva
O S
OS
Epstein
O I
OI
Yashkina
I V
IV
D000328:Adult; D000700:Analgesics / Q000276:immunology / Q000627:therapeutic use; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000276:immunology / Q000627:therapeutic use; D009020:Morphine / Q000276:immunology; D009293:Opioid-Related Disorders / Q000188:drug therapy; D009892:Opium; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
D000700:Analgesics; D000906:Antibodies; D006993:Hypnotics and Sedatives; D009020:Morphine; D009892:Opium